• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Zai Lab Limited - American Depositary Shares (NQ:ZLAB)

    25.36 -0.11 (-0.41%)
    Streaming Delayed Price Updated: 10:07 AM EDT, Sep 1, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 156,975
    Open 25.05
    Bid (Size) 25.33 (200)
    Ask (Size) 25.38 (200)
    Prev. Close 25.46
    Today's Range 24.81 - 25.41
    52wk Range 15.96 - 34.72
    Shares Outstanding 956,637,360
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
    From Zai Lab Limited
    Via Business Wire
    News headline image
    Zai Lab (ZLAB) Q2 2026 Earnings Call Transcript ↗
    Zoci advances toward global registrational trials as net product revenue rises 11%. 
    Via The Motley Fool
    Topics Earnings

    Performance

    YTD
    +46.3%
    +46.3%
    1 Month
    +39.5%
    +39.5%
    3 Month
    +48.4%
    +48.4%
    6 Month
    +37.6%
    +37.6%
    1 Year
    -24.0%
    -24.0%

    More News

    Read More
    News headline image
    Zai Lab Q2 Earnings Call Highlights ↗
    Via MarketBeat
    Topics Earnings
    News headline image
    Zai Lab Announces Second Quarter 2026 Financial Results and Recent Corporate Updates
    From Zai Lab Limited
    Via Business Wire
    News headline image
    U.S. FDA Grants Orphan Drug Designation to Zai Lab’s DLL3-Targeting ADC Zocilurtatug Pelitecan (Zoci) for the Treatment of Neuroendocrine Carcinomas (NECs)
    From Zai Lab Limited
    Via Business Wire
    News headline image
    Zai Lab to Announce Second Quarter 2026 Financial Results and Recent Corporate Updates on August 6, 2026
    From Zai Lab Limited
    Via Business Wire
    News headline image
    Zai Lab Receives EMA Orphan Drug Designation for Zocilurtatug Pelitecan (Zoci) in Pulmonary Neuroendocrine Carcinomas
    From Zai Lab Limited
    Via Business Wire
    News headline image
    Zai Lab Receives China NMPA Approval of TIVDAK® (tisotumab vedotin for injection) for the Treatment of Adult Patients with Recurrent or Metastatic Cervical Cancer
    From Zai Lab Limited
    Via Business Wire
    News headline image
    Zai Lab (ZLAB) Q1 2026 Earnings Transcript ↗
    Via The Motley Fool
    News headline image
    Zai Lab Announces Changes to Senior Leadership Team
    From Zai Lab Limited
    Via Business Wire
    News headline image
    Why a $5 Million New Position Signals Confidence in This Epilepsy Drug Pipeline ↗
    Via The Motley Fool
    Topics Intellectual Property Regulatory Compliance
    News headline image
    Why This Fund Added $12 Million to a Biotech Stock That's Now Down 58% in a Year ↗
    Via The Motley Fool
    Topics Economy Regulatory Compliance
    News headline image
    Zai Lab Receives U.S. FDA Fast Track Designation for Zocilurtatug Pelitecan (Zoci), a DLL3-Targeting ADC, for Treatment of Extrapulmonary Neuroendocrine Carcinomas (epNECs)
    From Zai Lab Limited
    Via Business Wire
    News headline image
    Zai Lab Q1 Earnings Call Highlights ↗
    Via MarketBeat
    Topics Earnings
    News headline image
    Zai Lab Announces First Quarter 2026 Financial Results and Recent Corporate Updates
    From Zai Lab Limited
    Via Business Wire
    News headline image
    Zai Lab to Announce First Quarter 2026 Financial Results and Recent Corporate Updates on May 7, 2026
    From Zai Lab Limited
    Via Business Wire
    News headline image
    Zai Lab Presents New Preclinical Data Suggesting ZL-1503, an IL-13/IL-31Rα Bispecific Antibody, Provides Rapid Itch Relief and Reduction in Inflammation in Atopic Diseases
    From Zai Lab Limited
    Via Business Wire
    News headline image
    Zai Lab Presents New Data Demonstrating Zocilurtatug Pelitecan (Zoci) Induces Rapid and Robust Intracranial Responses in Small Cell Lung Cancer with Brain Metastases and Promising Activity in Other Neuroendocrine Carcinomas
    From Zai Lab Limited
    Via Business Wire
    News headline image
    Zai Lab Announces Global Clinical Trial Collaboration and Supply Agreement to Evaluate Novel DLL3 ADC, Zocilurtatug Pelitecan, in Combination with a Bispecific T-cell Engager Therapy
    From Zai Lab Limited
    Via Business Wire
    News headline image
    Zai Lab to Present New Data on Three Internally Developed Oncology Candidates at AACR 2026, Including Zocilurtatug Pelitecan, a DLL3-Targeting Antibody-Drug Conjugate (ADC)
    From Zai Lab Limited
    Via Business Wire
    News headline image
    Zai Lab Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates
    From Zai Lab Limited
    Via Business Wire
    News headline image
    Zai Lab to Announce Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates on February 26, 2026
    From Zai Lab Limited
    Via Business Wire
    News headline image
    Zai Lab Highlights Strategic Priorities and Global Pipeline Progress at 44th Annual J.P. Morgan Healthcare Conference
    From Zai Lab Limited
    Via Business Wire
    News headline image
    Zai Lab Announces National Medical Products Administration (NMPA) Approval of AUGTYRO™ (repotrectinib) for Patients with NTRK-Positive Solid Tumors
    From Zai Lab Limited
    Via Business Wire
    News headline image
    Zai Lab to Present at 44th Annual J.P. Morgan Healthcare Conference
    From Zai Lab Limited
    Via Business Wire

    Frequently Asked Questions

    Is Zai Lab Limited - American Depositary Shares publicly traded?
    Yes, Zai Lab Limited - American Depositary Shares is publicly traded.
    What exchange does Zai Lab Limited - American Depositary Shares trade on?
    Zai Lab Limited - American Depositary Shares trades on the Nasdaq Stock Market
    What is the ticker symbol for Zai Lab Limited - American Depositary Shares?
    The ticker symbol for Zai Lab Limited - American Depositary Shares is ZLAB on the Nasdaq Stock Market
    What is the current price of Zai Lab Limited - American Depositary Shares?
    The current price of Zai Lab Limited - American Depositary Shares is 25.36
    When was Zai Lab Limited - American Depositary Shares last traded?
    The last trade of Zai Lab Limited - American Depositary Shares was at 09/01/26 10:07 AM ET
    What is the market capitalization of Zai Lab Limited - American Depositary Shares?
    The market capitalization of Zai Lab Limited - American Depositary Shares is 24.26B
    How many shares of Zai Lab Limited - American Depositary Shares are outstanding?
    Zai Lab Limited - American Depositary Shares has 24B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.